Stock overview
Regeneron Pharmaceuticals
Explore the company, reported ownership, price history, and available source evidence.
Regeneron develops biotechnology medicines for eye disease, immunology, oncology, cardiovascular disease, and rare conditions.
- Last close
- $945.53
- · REGN
- Tracked holders
- 3 funds
- Latest available 13F per fund
REGN · USD
Price
Close · Nov 18, 2026
- Range low
- $726.47
- Range high
- $973.36
- Observations
- 68
- Session date
- Nov 18, 2026
Aug 14, 2026–Nov 18, 2026. Regular market hours only. Historical prices are unadjusted; splits and other corporate actions can affect comparisons.
Investor Popularity
Rows are narrowed by movement, fund type, and position size.
| Fund | Move | Value | Weight |
|---|---|---|---|
| Renaissance Technologies largest tracked holder Q3 2026 · filed Nov 12, 2026 · SEC filing | +84% 26'Q3 | $206,414,743 | 0.28% |
| Gotham Asset Management position history Q3 2026 · filed Nov 16, 2026 · SEC filing | −17% 26'Q3 | $65,999,821 | 0.13% |
| Tudor Investment Corp position history Q3 2026 · filed Nov 16, 2026 · SEC filing | Newly reported 26'Q3 | $28,513,985 | 0.04% |
SEC Forms 4/5
Insiders
Financials
Official-source analysis
AI Earnings Report
No published AI Earnings Report yet
We publish a cited AI Earnings Report after an eligible official earnings filing is accepted and passes validation.
Options market